Patent Royalties. Subject to the provisions of Section 5.4.1(b), Merck shall pay Company royalties in an amount equal to the following percentage of Net Sales of Products by Merck or its Related Parties where the sale of Product would infringe a Valid Patent Claim in the country of sale:
Appears in 6 contracts
Samples: Exclusive License and Research Collaboration Agreement (Proteostasis Therapeutics, Inc.), Exclusive Patent License and Research Collaboration Agreement, Exclusive Patent License and Research Collaboration Agreement
Patent Royalties. Subject to the other provisions of this Section 5.4.1(b)5.6, on a Product-by-Product basis, Merck shall pay Company Ablynx royalties in an amount equal to the following percentage of Net Sales of Products a given Product sold by Merck or its Related Parties where in a given Calendar Year in countries in the Territory, provided that such sale of such Product would infringe a Valid Patent Claim in the country of sale, but for the license grant under this Agreement:
Appears in 5 contracts
Samples: Research Collaboration and Exclusive License Agreement (Ablynx NV), Research Collaboration and Exclusive License Agreement (Ablynx NV), Research Collaboration and Exclusive License Agreement (Ablynx NV)
Patent Royalties. Subject to the provisions of Section 5.4.1(b)5.3.3, on a Product-by-Product basis, Merck shall pay Company Chimerix royalties in an amount equal to the following percentage of aggregate Net Sales of Products a given Product sold by Merck or its Related Parties where in countries in the Territory for use in the Field, provided that the sale of such Product by Merck or its Related Parties would infringe a Valid Patent Claim in the country of sale:
Appears in 2 contracts
Samples: Collaboration and Exclusive License Agreement (Chimerix Inc), Collaboration and Exclusive License Agreement (Chimerix Inc)
Patent Royalties. Subject to the provisions of Section 5.4.1(b), Merck shall pay Company Cocrystal royalties in an amount equal to the following percentage of Net Sales of Products by Merck or and its Related Parties where the sale of Product would infringe a Valid Patent Claim in the country of sale:sale (“Patent Net Sales”):
Appears in 1 contract
Samples: License and Research Collaboration Agreement (Cocrystal Pharma, Inc.)
Patent Royalties. Subject to the provisions of Section 5.4.1(b5.2.3(a)(ii), Merck shall pay Company royalties in an amount equal to the following percentage of Net Sales of Products by Merck or its Related Parties where the sale of Product would infringe a Valid Patent Claim in the country of sale; provided that a Competitive Product is not sold in the country of sale:
Appears in 1 contract
Patent Royalties. Subject to the other provisions of this Section 5.4.1(b)5.2, Merck shall pay Company SurModics royalties in an amount equal to the following a certain percentage of Net Sales of Products by Merck or its Related Parties where as set forth below; provided that the sale of Product such Products would infringe a Valid Patent Claim in the country of sale:sale but for the licenses granted to Merck by SurModics (“Patent Royalty”):
Appears in 1 contract
Samples: Exclusive License and Research Collaboration Agreement (Surmodics Inc)
Patent Royalties. Subject to the provisions of Section 5.4.1(b), Merck shall pay Company Idera royalties in an amount equal to the following a certain percentage of Net Sales of Products Product(s) by Merck or its Related Parties where as set forth below, provided that the sale of Product such Product(s) would infringe a Valid Patent Claim in the country of sale:sale ("PATENT ROYALTY"):
Appears in 1 contract
Samples: Exclusive License and Research Collaboration Agreement (Idera Pharmaceuticals, Inc.)
Patent Royalties. Subject to the provisions of Section 5.4.1(b)7.4.1.2, Merck shall pay Company Sutro royalties in an amount equal to the following percentage of Net Sales of Products by Merck or its Related Parties where the sale of Product would infringe a Valid Patent Claim in the country of sale:
Appears in 1 contract
